← Human Trials & Peer-Reviewed Studies
Cardiopulmonary effects of endothelin-1 in man
Plain-language guide to PMID 9074702 (1997): double-blind randomized controlled trial study of Endothelin-1.
Key Facts
- PMID
- 9074702
- Journal
- Cardiovascular research
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Kiely DG et al. (4 authors)
- DOI
- 10.1016/s0008-6363(96)00219-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Endothelin-1, published as a randomized controlled trial.
Endothelin-1 levels are elevated in a number of conditions characterised by impaired cardiovascular performance and abnormal vasoconstriction such as congestive cardiac failure and primary and secondary pulmonary hypertension.
The aim of the present study was to assess the effects of the vasoconstrictor peptide endothelin-1 on pulmonary and systemic haemodynamics and cardiovascular performance in normal man.
Who Took Part
PubMed indexes the participants as adults, men only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
The participants were allocated by chance, so the Endothelin-1 group and the comparison group should start out alike.
As a double-blind Endothelin-1 study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Endothelin-1 could be set against what happens without it.
Each person switched between Endothelin-1 and the comparison at some point, usually with a gap in between.
Systemic and pulmonary haemodynamic parameters were monitored non-invasively by pulsed-wave Doppler, as were parameters of left and right ventricular diastolic filling and inotropic state.
Effects on renin-angiotensin and natriuretic peptide system activity were also measured.
What Was Measured
Topics PubMed links to this paper include Atrial Natriuretic Factor, Blood Pressure, Depression, Chemical, Diastole, Echocardiography, Doppler, Electrocardiography and Endothelin-1.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Endothelin-1.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1997 (Cardiovascular research), a journal based in England.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.